These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 14649076)

  • 1. [New drug against lipid disorders. HDL level rises 30%].
    MMW Fortschr Med; 2003 Sep; 145(39):51. PubMed ID: 14649076
    [No Abstract]   [Full Text] [Related]  

  • 2. [Lipid therapy in risk patients. Do we concentrate too much on LDL cholesterol?].
    März W
    MMW Fortschr Med; 2005 Apr; 147(14):14. PubMed ID: 15887675
    [No Abstract]   [Full Text] [Related]  

  • 3. Adipokines and treatment with niacin.
    Westphal S; Borucki K; Taneva E; Makarova R; Luley C
    Metabolism; 2006 Oct; 55(10):1283-5. PubMed ID: 16979396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current drug treatments for lipid management.
    Stone NJ
    Manag Care; 2002 Sep; 11(9 Suppl):4-9. PubMed ID: 12369341
    [No Abstract]   [Full Text] [Related]  

  • 5. Nicotinic acid in the treatment of hyperlipidaemia.
    Drexel H
    Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():5-6. PubMed ID: 18001312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug treatment of hyperlipidemia].
    Noseda G
    Ther Umsch; 1987 Aug; 44(8):578-83. PubMed ID: 3672411
    [No Abstract]   [Full Text] [Related]  

  • 7. New perspectives on the use of niacin in the treatment of lipid disorders.
    McKenney J
    Arch Intern Med; 2004 Apr; 164(7):697-705. PubMed ID: 15078639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
    Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C;
    Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors].
    Broncel M; Balcerak M; Chojnowska-Jezierska J
    Pol Merkur Lekarski; 2007 Jan; 22(127):62-5. PubMed ID: 17477094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin.
    Ito MK
    Ann Pharmacother; 2004 Feb; 38(2):277-85. PubMed ID: 14742767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antioxidant versus lipid-altering therapy--some answers, more questions.
    Freedman JE
    N Engl J Med; 2001 Nov; 345(22):1636-7. PubMed ID: 11757512
    [No Abstract]   [Full Text] [Related]  

  • 12. Experience with crystalline niacin as the preferred drug for dyslipidemia in a specialty clinic.
    Rindone JP; Arriola OG
    Pharmacotherapy; 1997; 17(6):1296-9. PubMed ID: 9399614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
    Birjmohun RS; Hutten BA; Kastelein JJ; Stroes ES
    J Am Coll Cardiol; 2005 Jan; 45(2):185-97. PubMed ID: 15653014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for raising HDL cholesterol.
    Harv Heart Lett; 2001 Nov; 12(3):5-6. PubMed ID: 11724689
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS; Kashyap ML
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing niacin as an atherosclerosis therapeutic agent valuable insights provided by high-resolution vascular magnetic resonance imaging.
    Jaffer FA
    J Am Coll Cardiol; 2009 Nov; 54(19):1795-6. PubMed ID: 19874993
    [No Abstract]   [Full Text] [Related]  

  • 18. [Use of prolonged-release nicotinic acid in patients treated with statins as a secondary prevention and a persistently low HDL-cholesterol level in France].
    Paillard F; Mosnier M
    Ann Cardiol Angeiol (Paris); 2008 Apr; 57(2):121-6. PubMed ID: 18394585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-density lipoprotein cholesterol and coronary heart disease.
    Young CE; Karas RH; Kuvin JT
    Cardiol Rev; 2004; 12(2):107-19. PubMed ID: 14766026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders.
    Vo AN; Kashyap ML
    Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1303-10. PubMed ID: 19018682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.